Vetoquinol S.A (VETO) | Financial Analysis & Statements
Vetoquinol S.A. Mid-cap Healthcare
TL;DR: Financial Overview - Revenue, Profits & Key Metrics
Income Metrics
Balance Sheet Metrics
Total Assets
725.8M
Total Liabilities
158.3M
Shareholders Equity
567.5M
Debt to Equity
0.28
Cash Flow Metrics
Revenue & Profitability Trend
Annual Income Flow
2024
Vetoquinol S.A Income Statement From 2020 to 2024
| Metric | 2024 | 2023 | 2022 | 2021 | 2020 |
|---|---|---|---|---|---|
| Revenue | 539.2M | 529.3M | 539.8M | 521.3M | 427.5M |
| Cost of Goods Sold | 151.7M | 156.6M | 159.6M | 150.7M | 129.8M |
| Gross Profit | 387.4M | 372.6M | 380.1M | 370.5M | 297.6M |
| Gross Margin % | 71.9% | 70.4% | 70.4% | 71.1% | 69.6% |
| Operating Expenses | |||||
| Research & Development | 2.4M | 1.8M | 2.8M | 2.9M | 3.1M |
| Selling, General & Administrative | 102.2M | 96.2M | 95.5M | 93.5M | 69.4M |
| Other Operating Expenses | 5.3M | 12.2M | 11.4M | 6.1M | 10.7M |
| Total Operating Expenses | 109.9M | 110.2M | 109.8M | 102.4M | 83.2M |
| Operating Income | 76.3M | 77.8M | 84.3M | 85.8M | 56.4M |
| Operating Margin % | 14.1% | 14.7% | 15.6% | 16.5% | 13.2% |
| Non-Operating Items | |||||
| Interest Income | 5.9M | 3.3M | 807.0K | 366.0K | 623.0K |
| Interest Expense | 1.1M | 918.0K | 999.0K | 617.0K | 827.0K |
| Other Non-Operating Income | - | - | - | - | - |
| Pre-tax Income | 81.0M | 76.9M | 72.7M | 86.5M | 35.6M |
| Income Tax | 22.3M | 21.3M | 24.7M | 23.8M | 16.6M |
| Effective Tax Rate % | 27.6% | 27.7% | 34.0% | 27.5% | 46.8% |
| Net Income | 58.7M | 55.6M | 48.0M | 62.9M | 19.2M |
| Net Margin % | 10.9% | 10.5% | 8.9% | 12.1% | 4.5% |
| Key Metrics | |||||
| EBITDA | 113.0M | 115.8M | 116.9M | 119.5M | 83.2M |
| EPS (Basic) | €4.98 | €4.70 | €4.06 | €5.31 | €1.63 |
| EPS (Diluted) | €4.98 | €4.70 | €4.06 | €5.31 | €1.63 |
| Basic Shares Outstanding | 11795673 | 11832510 | 11831588 | 11827762 | 11826157 |
| Diluted Shares Outstanding | 11795673 | 11832510 | 11831588 | 11827762 | 11826157 |
Income Statement Trend
Vetoquinol S.A Balance Sheet From 2020 to 2024
| Metric | 2024 | 2023 | 2022 | 2021 | 2020 |
|---|---|---|---|---|---|
| Assets | |||||
| Current Assets | |||||
| Cash & Equivalents | 206.3M | 147.5M | 93.7M | 69.0M | 129.4M |
| Short-term Investments | - | - | - | - | - |
| Accounts Receivable | 86.8M | 89.3M | 74.6M | 77.5M | 72.7M |
| Inventory | 112.3M | 103.5M | 116.1M | 111.6M | 85.5M |
| Other Current Assets | 5.0K | 1.0K | - | - | -1.0K |
| Total Current Assets | 421.2M | 363.4M | 308.6M | 273.7M | 307.2M |
| Non-Current Assets | |||||
| Property, Plant & Equipment | 17.8M | 21.3M | 17.0M | 18.0M | 19.3M |
| Goodwill | 294.9M | 304.1M | 321.1M | 345.4M | 334.7M |
| Intangible Assets | 142.1M | 154.0M | 168.7M | 178.5M | 175.0M |
| Long-term Investments | - | - | - | - | - |
| Other Non-Current Assets | - | - | - | - | 1.0K |
| Total Non-Current Assets | 323.0M | 328.8M | 343.2M | 350.9M | 338.9M |
| Total Assets | 744.1M | 692.2M | 651.8M | 624.6M | 646.1M |
| Liabilities | |||||
| Current Liabilities | |||||
| Accounts Payable | 39.4M | 42.0M | 39.0M | 46.9M | 41.5M |
| Short-term Debt | 9.9M | 8.0M | 7.9M | 8.3M | 116.6M |
| Current Portion of Long-term Debt | - | - | - | - | - |
| Other Current Liabilities | 1.0K | 2.0K | 11.0K | 9.0K | 251.0K |
| Total Current Liabilities | 141.5M | 139.4M | 140.7M | 157.0M | 239.6M |
| Non-Current Liabilities | |||||
| Long-term Debt | 11.2M | 9.7M | 9.6M | 7.1M | 8.3M |
| Deferred Tax Liabilities | 6.0M | 7.2M | 8.0M | 8.3M | 8.4M |
| Other Non-Current Liabilities | 684.0K | 721.0K | 817.0K | 825.0K | 6.1M |
| Total Non-Current Liabilities | 26.7M | 25.7M | 26.5M | 26.2M | 34.7M |
| Total Liabilities | 168.2M | 165.1M | 167.2M | 183.2M | 274.3M |
| Equity | |||||
| Common Stock | 29.7M | 29.7M | 29.7M | 29.7M | 29.7M |
| Retained Earnings | 58.7M | 55.6M | 48.0M | 62.9M | 19.2M |
| Treasury Stock | - | - | - | - | - |
| Other Equity | - | - | - | - | - |
| Total Shareholders Equity | 575.9M | 527.1M | 484.7M | 441.4M | 371.8M |
| Key Metrics | |||||
| Total Debt | 21.1M | 17.6M | 17.4M | 15.4M | 124.9M |
| Working Capital | 279.6M | 224.0M | 167.9M | 116.7M | 67.6M |
Balance Sheet Composition
Vetoquinol S.A Cash Flow Statement From 2020 to 2024
| Metric | 2024 | 2023 | 2022 | 2021 | 2020 |
|---|---|---|---|---|---|
| Operating Activities | |||||
| Net Income | 58.7M | 55.6M | 48.0M | 62.9M | 19.2M |
| Depreciation & Amortization | - | - | - | - | - |
| Stock-Based Compensation | 0 | 0 | 51.0K | 129.0K | 78.0K |
| Working Capital Changes | 0 | 0 | 0 | 0 | 0 |
| Operating Cash Flow | 54.7M | 54.3M | 48.8M | 90.0M | 19.8M |
| Investing Activities | |||||
| Capital Expenditures | -12.5M | -14.8M | -16.4M | -32.1M | -10.2M |
| Acquisitions | 0 | 0 | 904.0K | -1.2M | 0 |
| Investment Purchases | -47.0K | -10.0K | -504.0K | -74.0K | 0 |
| Investment Sales | - | - | - | - | 141.0K |
| Investing Cash Flow | -12.5M | -14.8M | -16.0M | -33.4M | -10.0M |
| Financing Activities | |||||
| Share Repurchases | -2.9M | 0 | 0 | 0 | -243.0K |
| Dividends Paid | -10.1M | -9.5M | -9.5M | -5.9M | -4.5M |
| Debt Issuance | 845.0K | 1.0M | 2.2M | 1.5M | 112.1M |
| Debt Repayment | -1.9M | -2.6M | -2.4M | -110.6M | -89.0K |
| Financing Cash Flow | -8.9M | -8.9M | -9.4M | -114.9M | 107.6M |
| Free Cash Flow | 68.1M | 70.4M | 40.4M | 57.3M | -53.2M |
| Net Change in Cash | 33.2M | 30.7M | 23.4M | -58.3M | 117.4M |
Cash Flow Trend
Vetoquinol S.A Key Financial Ratios
No financial ratio data available.
Peer Financial Comparison
| Company | Market Cap | P/E Ratio | P/B Ratio | ROE | Profit Margin | Debt/Equity |
|---|---|---|---|---|---|---|
| Ipsen S.A | 13.4B | 30.83 | 3.12 | 10.44% | 11.29% | 22.38 |
| Boiron S.A | 446.2M | 23.15 | 1.21 | 5.22% | 3.84% | 4.90 |
| Euroapi S.A.S.U | 121.5M | 8.84 | 0.20 | -23.84% | -24.77% | 8.30 |
| AB Science S.A | 76.8M | -7.73 | - | 32.97% | 116.42% | -0.80 |
| CoreTech Limited | 1.3M | - | - | -102.42% | 137.36% | -1.03 |
Financial data is updated regularly. All figures are in the company's reporting currency.